AstraZeneca Unit Dodges PTAB Review For $2B Cancer Drug
The Patent Trial and Appeal Board has denied Sandoz Inc.'s challenge to a patent covering Calquence, a cancer drug which had more than $2 billion in sales for AstraZeneca last year....To view the full article, register now.
Already a subscriber? Click here to view full article